ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0420

Myeloid IRF4 Deficiency Attenuates Peritoneal Fibrosis by Suppressing Macrophage Migration

Session Information

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Sasaki, Kensuke, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
  • Onoue, Keiko, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
  • Ike, Takeshi, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
  • Osaki, Yosuke, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
  • Ishiuchi, Naoki, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
  • Maeoka, Yujiro, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
  • Masaki, Takao, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
Background

Interferon regulatory factor 4 (IRF4) is a transcription factor involved in the regulation of immune responses, but its role in peritoneal inflammation and fibrosis remains poorly understood. This study aimed to elucidate the impact of myeloid-specific IRF4 deficiency on peritoneal fibrosis and macrophage function and polarization.

Methods

We utilized LysM-Cre IRF4fl/fl mice (MφIRF4-KO) and induced peritoneal fibrosis using methylglyoxal (MGO), a well-established agent for modeling peritoneal injury. Inflammatory and fibrotic changes in the peritoneum were compared between MφIRF4-KO and control mice. Transwell assays were performed to evaluate macrophage migratory capacity, and in vitro stimulation was conducted using advanced glycation end-products (AGEs) and the chemokine CCL2. CCR2 expression and AKT phosphorylation were assessed via flow cytometry, immunofluorescence, and immunoblotting.

Results

MφIRF4-KO mice demonstrated reduced macrophage infiltration in peritoneal tissues, along with attenuated inflammation and fibrosis, resulting in improved peritoneal function. Histological analysis showed decreased thickening of the submesothelial compact zone and reduced fibrotic change, as confirmed by HE and Masson's trichrome staining. Expression of pro-fibrotic markers such as collagen1 was significantly downregulated in the peritoneum of MφIRF4-KO mice. Migration assays revealed impaired motility of peritoneal macrophages in MφIRF4-KO mice. These macrophages exhibited reduced responsiveness to chemotactic stimuli, suggesting a defect in migration. Mechanistically, these macrophages showed diminished AKT phosphorylation and significantly downregulated expression of the chemokine receptor CCR2. Flow cytometry confirmed a reduced CCR2 positive macrophage population in MφIRF4-KO mice, indicating that IRF4 influence macrophage migratory capacity.

Conclusion

Myeloid-specific IRF4 deficiency suppresses macrophage migration by downregulating CCR2 expression and AKT signaling, thereby mitigating peritoneal inflammation and fibrosis. IRF4 may serve as a novel therapeutic target for the treatment of peritoneal fibrosis.

Digital Object Identifier (DOI)